{"disease":{"id":"locally-advanced-operable","name":"locally advanced operable"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04862663","title":"Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":895,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04305496","title":"Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT03911219","title":"Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus Chemotherapy","phase":"","overall_status":"COMPLETED","enrollment_count":154,"lead_sponsor_name":"iOMEDICO AG","has_results":false},{"nct_id":"NCT07008742","title":"Feasibility Study of Tissue and Blood Collection in Oncogene-addicted and Neoadjuvantly Treated Non Small Cell Lung Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Royal Marsden NHS Foundation Trust","has_results":false},{"nct_id":"NCT06107114","title":"Cetuximab+Zimberelimab in Combination With Cisplatin and Nab-paclitaxel in Resctable Head and Neck Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":52,"lead_sponsor_name":"Xuekui Liu","has_results":false},{"nct_id":"NCT06023875","title":"Neoadjuvant Cadonilimab in Combination With Cisplatin and Nab-paclitaxel in Resectable Head and Neck Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Xuekui Liu","has_results":false},{"nct_id":"NCT03600623","title":"Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer","phase":"EARLY_PHASE1","overall_status":"TERMINATED","enrollment_count":25,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":false},{"nct_id":"NCT04652206","title":"Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":18,"lead_sponsor_name":"Scandion Oncology A/S","has_results":false}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}